| Not Yet Recruiting | HEPATITIS C SCREENING in ADULTS with RISK FACTORS in FIVE CITIES of COLOMBIA'S CARIBBEAN COAST (FIVE-CC) NCT06899542 | Diana Rocio Chavez Bejarano | — |
| Unknown | Therapeutic Hepatitis C Virus Vaccine NCT04318379 | GeneCure Biotechnologies | Phase 1 |
| Withdrawn | Triple Combination DAAs for Treating HCV GT1b Subjects NCT02932293 | Humanity and Health Research Centre | Phase 2 |
| Completed | A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects NCT02486406 | AbbVie | Phase 2 / Phase 3 |
| Terminated | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or NCT02504099 | AbbVie | Phase 3 |
| Completed | Switching Regimen in Treating Cirrhotic HCV GT1b Subjects NCT02583685 | Humanity and Health Research Centre | Phase 2 |
| Completed | Follow up of IFN Vs DAAs HCV SVR (IFDACS Study) NCT02578693 | Humanity and Health Research Centre | — |
| Completed | Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients NCT02576314 | Humanity and Health Research Centre | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infec NCT02442271 | AbbVie | Phase 3 |
| Completed | A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct- NCT02356562 | AbbVie | Phase 2 |
| Completed | DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) NCT02555943 | Humanity and Health Research Centre | Phase 2 / Phase 3 |
| Completed | Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects NCT02470858 | Humanity and Health Research Centre | Phase 2 |
| Completed | Neutrino Regimen for Treatment-experienced HCV GT1 Patients NCT02480686 | Humanity and Health Research Centre | Phase 4 |
| Completed | Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients NCT02482077 | Humanity and Health Research Centre | Phase 4 |
| Completed | SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients NCT02473211 | Humanity and Health Research Centre | Phase 2 / Phase 3 |
| Completed | Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions NCT02333292 | Valme University Hospital | — |
| Completed | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With NCT02219503 | AbbVie | Phase 3 |
| Completed | The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis NCT01711164 | University Health Network, Toronto | — |
| Completed | Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults NCT02023099 | AbbVie | Phase 3 |
| Terminated | Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Sub NCT01866930 | Bristol-Myers Squibb | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed P NCT01854528 | AbbVie | Phase 3 |
| Unknown | Clinical Investigation of Erlotinib as an HCV Entry Inhibitor NCT01835938 | University Hospital, Strasbourg, France | Phase 1 / Phase 2 |
| Completed | An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adu NCT01911845 | AbbVie | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed P NCT01854697 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection NCT01833533 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients NCT01782495 | AbbVie | Phase 2 |
| Completed | To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Pa NCT01813552 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) NCT01813513 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection NCT01767116 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults NCT01715415 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | A Study to Evaluate Chronic Hepatitis C Infection NCT01716585 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients NCT02065999 | Kirby Institute | — |
| Completed | A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) a NCT01704755 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive He NCT01700179 | Alexion Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-2 NCT01674725 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Terminated | Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity NCT01651767 | Janssen R&D Ireland | Phase 1 |
| Completed | A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C NCT01672983 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Terminated | A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Dos NCT01586325 | Janssen R&D Ireland | Phase 1 |
| Completed | Herpes Simplex Type 1 Suppression in Hepatitis C NCT01580995 | VA Office of Research and Development | Phase 2 |
| Completed | Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected S NCT01563536 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I) NCT01453075 | VA Office of Research and Development | Phase 1 |
| Completed | A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 NCT01194037 | HanAll BioPharma Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Metformin Therapy in HCV Infection NCT02972723 | Nottingham University Hospitals NHS Trust | Phase 4 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Give NCT01306617 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT NCT01260350 | Gilead Sciences | Phase 2 |
| Completed | A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With R NCT01221298 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Pre NCT01225380 | Gilead Sciences | Phase 2 |
| Completed | Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis NCT00854087 | Tarek Hassanein | Phase 2 |
| Completed | Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Pat NCT01055821 | Transgene | Phase 2 |
| Completed | A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 NCT01074008 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Terminated | Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009- NCT00954993 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004) NCT01011166 | Merck Sharp & Dohme LLC | Phase 2 |
| Withdrawn | Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy NCT00682591 | University of Wuerzburg | — |
| Completed | Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults NCT00557583 | Virobay Inc. | Phase 1 |
| Terminated | Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With F NCT00274495 | Beth Israel Medical Center | Phase 4 |
| Completed | The Role of Dendritic Cells in Hepatitis C Infection NCT00723242 | University College, London | N/A |